Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type, Route of Administration, Disease Type, Application, and Region

Description

List of Tables

The global vaccine adjuvants market size is expected to reach USD 6,035.04 million by 2034, according to a new study by Polaris Market Research. The report "Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Alum, and Others), Route of Administration, Disease Type, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The vaccine adjuvants market involves substances added to vaccines to enhance immune responses. These adjuvants improve the efficacy of vaccines, particularly for challenging diseases. Growing demand for vaccines, advancements in adjuvant technologies, and increased awareness of immunization are driving market growth. Key players focus on developing new adjuvants with improved safety and effectiveness. The market is fueled by rising vaccination programs and the need for vaccines against emerging diseases, including COVID-19.

The vaccine adjuvants market growth is driven by the increasing demand for effective vaccines, particularly for infectious diseases and cancer immunotherapy. Key drivers include the rising incidence of infectious diseases across the world, increasing need for enhanced vaccine efficacy, and continued government and private sector investments in vaccine development. Vaccine adjuvants market opportunities lie in the development of next-generation adjuvants with better safety profiles and the growing use of adjuvants in personalized medicine, including cancer vaccines. Market trends include a shift toward more advanced adjuvant technologies, such as liposome-based and saponin-based adjuvants, and the expansion of vaccine research in response to emerging health threats. Overall, the market is poised for steady growth, supported by innovation, strategic collaborations, and increasing healthcare needs worldwide.

Vaccine Adjuvants Market Report Highlights

Based on product type, the alum segment holds the largest market share due to its long-standing use in vaccines and proven safety. However, adjuvant emulsions are the fastest-growing segment, driven by their enhanced immune response in vaccines for infectious diseases and pandemics.

By route of administration, the intramuscular route segment dominates the market due to its widespread use in vaccines for various infectious diseases, such as influenza and COVID-19. The subcutaneous route is registering the highest growth, particularly in therapeutic vaccines and immunotherapy applications.

In terms of disease type, the infectious diseases segment dominates the vaccine adjuvants market revenue share, driven by ongoing vaccination programs for diseases such as influenza, hepatitis, and COVID-19. The cancer segment is experiencing the highest growth, fueled by advancements in immunotherapy vaccines and personalized medicine.

The commercial application segment, by application, leads the vaccine adjuvants market share owing to the widespread use of adjuvanted vaccines in public health initiatives globally. The research application segment is growing the fastest, supported by increased investments in vaccine development and clinical trials, especially in cancer and therapeutic vaccines.

North America holds the largest market share due to its strong healthcare infrastructure and substantial vaccine research investments. Asia Pacific is registering the highest growth, driven by expanding healthcare needs, large populations, and increasing vaccine adoption.

Polaris Market Research has segmented the vaccine adjuvants market report on the basis of product type, route of administration, disease type, application, and region:

By Product Type Outlook (Revenue - USD Million, 2020-2034)

Particulate Adjuvants
Adjuvant Emulsions
Pathogen Components
Alum
Others

By Route of Administration Outlook (Revenue - USD Million, 2020-2034)

Intramuscular Route
Subcutaneous Route
Others

By Disease Type Outlook (Revenue - USD Million, 2020-2034)

Infectious Diseases
Cancer
Others

By Application Outlook (Revenue - USD Million, 2020-2034)

Research Application
Commercial Application

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1684

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Vaccine Adjuvants Market Insights

4.1. Vaccine Adjuvants Market - Market Snapshot
4.2. Vaccine Adjuvants Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Focus on Advanced Adjuvant Technologies
  - 4.2.1.2. Growing Role of Adjuvants in Pandemic Preparedness
  - 4.2.1.3. Expansion of Personalized Vaccine Adjuvant Strategies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Regulatory Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Vaccine Adjuvants Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Vaccine Adjuvants Market, by Product Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
5.3. Particulate Adjuvants
- 5.3.1. Global Vaccine Adjuvants Market, by Particulate Adjuvants, by Region, 2020-2034 (USD Million)
5.4. Adjuvant Emulsions
- 5.4.1. Global Vaccine Adjuvants Market, by Adjuvant Emulsions, by Region, 2020-2034 (USD Million)
5.5. Pathogen Components
- 5.5.1. Global Vaccine Adjuvants Market, by Pathogen Components, by Region, 2020-2034 (USD Million)
5.6. Alum
- 5.6.1. Global Vaccine Adjuvants Market, by Alum, by Region, 2020-2034 (USD Million)
5.7. Others
- 5.7.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Vaccine Adjuvants Market, by Route of Administration

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
6.3. Intramuscular Route
- 6.3.1. Global Vaccine Adjuvants Market, by Intramuscular Route, by Region, 2020-2034 (USD Million)
6.4. Subcutaneous Route
- 6.4.1. Global Vaccine Adjuvants Market, by Subcutaneous Route, by Region, 2020-2034 (USD Million)
6.5. Others
- 6.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Vaccine Adjuvants Market, by Disease Type

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
7.3. Infectious Diseases
- 7.3.1. Global Vaccine Adjuvants Market, by Infectious Diseases, by Region, 2020-2034 (USD Million)
7.4. Cancer
- 7.4.1. Global Vaccine Adjuvants Market, by Cancer, by Region, 2020-2034 (USD Million)
7.5. Others
- 7.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Vaccine Adjuvants Market, by Application

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
8.3. Research Application
- 8.3.1. Global Vaccine Adjuvants Market, by Research Application, by Region, 2020-2034 (USD Million)
8.4. Commercial Application
- 8.4.1. Global Vaccine Adjuvants Market, by Commercial Application, by Region, 2020-2034 (USD Million)

9. Global Vaccine Adjuvants Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Vaccine Adjuvants Market Assessment, By Geography, 2020-2034 (USD Million)
9.3. Vaccine Adjuvants Market - North America
- 9.3.1. North America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.3.2. North America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.3.3. North America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.3.4. North America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.3.5. Vaccine Adjuvants Market - US
  - 9.3.5.1. US: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.3.5.2. US: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.3.5.3. US: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.3.5.4. US: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.3.6. Vaccine Adjuvants Market - Canada
  - 9.3.6.1. Canada: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.3.6.2. Canada: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.3.6.3. Canada: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.3.6.4. Canada: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.4. Vaccine Adjuvants Market - Europe
- 9.4.1. Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.4.2. Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.4.3. Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.4.4. Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.5. Vaccine Adjuvants Market - UK
  - 9.4.5.1. UK: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.5.2. UK: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.5.3. UK: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.5.4. UK: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.6. Vaccine Adjuvants Market - France
  - 9.4.6.1. France: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.6.2. France: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.6.3. France: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.6.4. France: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.7. Vaccine Adjuvants Market - Germany
  - 9.4.7.1. Germany: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.7.2. Germany: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.7.3. Germany: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.7.4. Germany: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.8. Vaccine Adjuvants Market - Italy
  - 9.4.8.1. Italy: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.8.2. Italy: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.8.3. Italy: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.8.4. Italy: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.9. Vaccine Adjuvants Market - Spain
  - 9.4.9.1. Spain: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.9.2. Spain: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.9.3. Spain: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.9.4. Spain: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.10. Vaccine Adjuvants Market - Netherlands
  - 9.4.10.1. Netherlands: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.10.2. Netherlands: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.10.3. Netherlands: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.10.4. Netherlands: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.11. Vaccine Adjuvants Market - Russia
  - 9.4.11.1. Russia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.11.2. Russia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.11.3. Russia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.11.4. Russia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.12. Vaccine Adjuvants Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.12.2. Rest of Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.12.3. Rest of Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.12.4. Rest of Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.5. Vaccine Adjuvants Market - Asia Pacific
- 9.5.1. Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.5. Vaccine Adjuvants Market - China
  - 9.5.5.1. China: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.5.2. China: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.5.3. China: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.5.4. China: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.6. Vaccine Adjuvants Market - India
  - 9.5.6.1. India: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.6.2. India: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.6.3. India: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.6.4. India: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.7. Vaccine Adjuvants Market - Malaysia
  - 9.5.7.1. Malaysia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.7.2. Malaysia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.7.3. Malaysia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.7.4. Malaysia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.8. Vaccine Adjuvants Market - Japan
  - 9.5.8.1. Japan: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.8.2. Japan: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.8.3. Japan: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.8.4. Japan: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.9. Vaccine Adjuvants Market - Indonesia
  - 9.5.9.1. Indonesia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.9.2. Indonesia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.9.3. Indonesia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.9.4. Indonesia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.10. Vaccine Adjuvants Market - South Korea
  - 9.5.10.1. South Korea: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.10.2. South Korea: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.10.3. South Korea: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.10.4. South Korea: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.11. Vaccine Adjuvants Market - Australia
  - 9.5.11.1. Australia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.11.2. Australia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.11.3. Australia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.11.4. Australia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.12. Vaccine Adjuvants Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.12.2. Rest of Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.12.3. Rest of Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.12.4. Rest of Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.6. Vaccine Adjuvants Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.5. Vaccine Adjuvants Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.5.2. Saudi Arabia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.5.3. Saudi Arabia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.5.4. Saudi Arabia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.6. Vaccine Adjuvants Market - UAE
  - 9.6.6.1. UAE: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.6.2. UAE: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.6.3. UAE: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.6.4. UAE: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.7. Vaccine Adjuvants Market - Israel
  - 9.6.7.1. Israel: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.7.2. Israel: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.7.3. Israel: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.7.4. Israel: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.8. Vaccine Adjuvants Market - South Africa
  - 9.6.8.1. South Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.8.2. South Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.8.3. South Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.8.4. South Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.9. Vaccine Adjuvants Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.9.2. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.9.3. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.9.4. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.7. Vaccine Adjuvants Market - Latin America
- 9.7.1. Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.7.2. Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.7.3. Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.7.4. Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.5. Vaccine Adjuvants Market - Mexico
  - 9.7.5.1. Mexico: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.5.2. Mexico: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.5.3. Mexico: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.5.4. Mexico: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.6. Vaccine Adjuvants Market - Brazil
  - 9.7.6.1. Brazil: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.6.2. Brazil: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.6.3. Brazil: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.6.4. Brazil: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.7. Vaccine Adjuvants Market - Argentina
  - 9.7.7.1. Argentina: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.7.2. Argentina: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.7.3. Argentina: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.7.4. Argentina: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.8. Vaccine Adjuvants Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.8.2. Rest of Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.8.3. Rest of Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.8.4. Rest of Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. GlaxoSmithKline (GSK)
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Novavax
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Merck & Co.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Sanofi
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. CSL Limited
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Adjuvance Technologies
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. SEPPIC
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Croda International
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Vaxine Pty Ltd
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Brenntag Biosector
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
11.11. Vaccitech (University of Oxford spin-off)
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
11.12. Emergent BioSolutions
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
11.13. Avanti Polar Lipids
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
11.14. Daiichi Sankyo
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
11.15. ImmunoScience
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development